Danaher (NYSE:DHR) Posts Earnings Results

Danaher (NYSE:DHR) released its earnings results on Tuesday. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26, Zacks reports. Danaher had a return on equity of 10.82% and a net margin of 16.33%. Danaher updated its FY 2025 guidance to 7.600-7.750 EPS.

Danaher Stock Performance

NYSE:DHR opened at $184.96 on Tuesday. Danaher has a twelve month low of $171.00 and a twelve month high of $281.70. The firm has a market cap of $132.19 billion, a price-to-earnings ratio of 35.03, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86. The company has a 50-day moving average of $201.64 and a 200-day moving average of $226.01. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.32 dividend. The ex-dividend date is Friday, March 28th. This is a boost from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a yield of 0.69%. Danaher’s payout ratio is 24.24%.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on DHR shares. Robert W. Baird set a $231.00 price objective on shares of Danaher in a report on Wednesday, April 16th. Wells Fargo & Company lowered their price objective on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. The Goldman Sachs Group upgraded Danaher from a “neutral” rating to a “buy” rating and set a $260.00 target price for the company in a research report on Friday, March 21st. Citigroup reiterated a “buy” rating on shares of Danaher in a research note on Monday, April 7th. Finally, Scotiabank assumed coverage on shares of Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $274.55.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.